Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fluocortolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 9/20 | 0.67 |
| ▸ | AR | P10275 | 6/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocortolone SCHEMBL21852268 | 0.97 | PGR (0.68) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL4644 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL19327147 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11862489 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL13902941 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11333890 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL3047399 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL21706397 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11518086 | 0.97 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL144059 | 0.96 | PGR (0.69) | PGRARADRA1ACHRM1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115956078-A | AKT3 modulators and methods of use thereof | 乔治穆内有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115867562-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-113195596-B | Branched organosilicon compounds, methods of making branched organosilicon compounds, and compositions comprising branched organosilicon compounds | 美国陶氏有机硅公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-113330054-B | Branched organosilicon compounds, methods of making, and copolymers formed therewith | 美国陶氏有机硅公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-113348199-B | Branched organosilicon compounds, methods of making branched organosilicon compounds, and copolymers formed therewith | 美国陶氏有机硅公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-113166423-B | Branched organosilicon compounds, method for producing branched organosilicon compounds, and compositions containing branched organosilicon compounds | 美国陶氏有机硅公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-115398231-A | Methods related to toxicity and response associated with cell therapy for treatment of B cell malignancies | 朱诺治疗学股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-114848506-A | Multifunctional personalized patch with therapeutic properties | 强生消费者公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634447-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-112312898-A | Three-dimensional microfluidic device for delivery of active substances | 强生消费者公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112312892-A | Three-dimensional microfluidic device for delivery of active substances | 强生消费者公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-111110850-A | Compositions and methods for preventing or treating diseases characterized by abnormal fibroblast proliferation and extracellular matrix deposition | 莫伊莱麦屈克斯公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-110772710-A | Method for enhancing topical application of benefit agents | 强生消费者公司 | 2020-02-11 | — | — | CN | disclosed |
| US-20120142605-A1 | METHODS OF TREATING PSORIASIS | AMGEN INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2010129707-A1 | ETANERCEPT IN COMBINATION WITH GLUCOCORTICOIDS FOR USE IN TREATING PSORIASIS | AMGEN INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4432964-A | Topical composition containing steroid in two forms released independently from polymeric carrier | ALZA CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-3933869-A | Preparation of organic radiohalogen compounds | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142605-A1 | METHODS OF TREATING PSORIASIS | TNF, TSLP, IL17A | ADRA2A 813/4885PGR 456/4885AR 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.